Phone: (330) 440-2502    Mail: info@interventionalheadache.net

Brief Communications

Brief Communications

AIHS Press Release and Newsletter - February 2017

Sphenopalatine ganglion stimulation in cluster headaches

Cluster headaches are characterized by severe debilitating pain which is often refractory to treatment. It is described in the ICDH-3 Beta headache criteria as consisting of attacks of severe, strictly unilateral pain which is orbital, supraorbital, temporal or in any combination of these sites, lasting 15-180 minutes and occurring from once every other day to eight times a day. The sphenopalatine ganglion (SPG) has been implicated in the pathophysiology of cluster headache, and therefore has been targeted to treat cluster headaches. In an article published in Cephalalgia, authors Láinez Marti reviewed the published literature on SPG stimulation and cluster headaches. An SPG stimulator is a device inserted by a minimally invasive procedure in which a neurostimulator directly and reversibly stimulates the area of the SPG. They found evidence that demonstrated that SPG stimulation is a safe and effective treatment for chronic refractory cluster headache patients, effective in both acute at- tacks and as a preventative treatment.

Read more here:http://journals.sagepub.com/doi/full/10.1177/0333102416644968


High Cervical Spinal Cord Stimulation for Refractory Headaches

High cervical spinal cord stimulation is a novel promising approach for the treatment of refractory chronic Cluster and Migraine headaches. This approach works by delivering electrical stimulation to trigeminocervical complex through implantable leads. The HF10 device was FDA approved in 2015 for chronic intractable trunk and/or extremity pain. Based on Trial results it is superior to conventional spinal cord stimulators in treatment for chronic back and leg pain as they do not produce uncomfortable paresthesias. Prospective open label study of using this system in refractory chronic migraine patients has shown at least 50% improvement in headache days. Feasibility studies for HF10 device in treatment of refractory chronic Migraine are ongoing.

Read more here: https://thejournalofheadacheandpain.springeropen.com/articles/10.1186/s10194-016-0657-2

Related Articles

Image
1970 N Cleveland Massillon Rd, #705 Bath, OH 44210
(330) 440-2502

info@interventionalheadache.net

Disclaimer Regarding Medical Information

American Interventional Headache Society™ (AIHS) website content as well as AIHS workshops contain information regarding suggested medical treatments and/or can initiate any medical treatment discussions. This information presents medical opinions and any medical care or treatment should not be solely made on the basis of this information. The accountability and judgement for proper medical treatment is the responsibility of the treating physician together with his/her patient.

Join Our Email List
 

The American Interventional Headache Society™ will use the information you provide on this form to be in touch with you and to provide updates and upcoming events. Please check box below to confirm that we can communicate with you via email.

You can change your mind at any time by clicking the unsubscribe link in the footer of any email you receive from us, or by contacting us at info@interventionalheadache.net. We will treat your information with respect. We use Mailchimp as our marketing platform. By clicking below, you agree that we may process your information in accordance with these terms.